2024-09-02 - Analysis Report
## ISRG Stock Analysis

**Company Overview:** Intuitive Surgical, Inc. (ISRG) is a leading provider of robotic-assisted surgical systems and instruments.

**1. Performance Comparison:**

ISRG has outperformed the S&P 500 (VOO) significantly. Its cumulative return of 159.33% is 69.67% higher than VOO's 89.66%. This puts ISRG at the 98.59th percentile of its historical performance relative to VOO. 

**2. Recent Price Movement:**

* **Closing Price:** 492.63
* **5-Day Moving Average:** 484.71
* **20-Day Moving Average:** 474.02
* **60-Day Moving Average:** 449.66

ISRG's price is above all moving averages, indicating a strong upward trend.

**3. Technical Indicators:**

* **RSI:** 75.94 (Overbought)
* **PPO:** -0.01 (Neutral)
* **Delta_Previous_Relative_Divergence:** -1.41 (Short-Term Downward Trend)
* **Expected Return:** 1.0% (Maximum 5-year expected return on invested capital)

The RSI suggests that ISRG is overbought, implying a potential for a pullback. However, the PPO indicates a neutral sentiment. The recent downward trend in relative divergence may also suggest some price correction in the near term. 

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-19 | 1.48 | 2.01 B$ | 
| 2024-04-19 | 1.54 | 1.89 B$ |
| 2023-10-20 | 1.18 | 1.74 B$ |
| 2023-07-24 | 1.2 | 1.76 B$ |
| 2024-07-19 | 1.2 | 1.76 B$ |

ISRG's most recent earnings for Q2 2024 were $1.48 per share, exceeding analyst expectations of $1.38. Revenue also beat expectations, reaching $2.01 billion against an anticipated $1.98 billion.  This indicates strong demand for ISRG's products and services, confirming the company's position as a leader in the robotic surgery market. 

**5. Overall Analysis:**

ISRG has shown exceptional long-term performance, significantly outperforming the market. The recent earnings beat supports the company's strong growth prospects and market leadership. However, the stock currently sits in overbought territory, potentially indicating a near-term pullback. 

**6. Conclusion:**

While ISRG exhibits impressive performance and strong fundamentals, its current overbought status warrants caution. It may be prudent to monitor the stock for potential price corrections in the short term. However, ISRG remains a compelling long-term investment opportunity given its dominant position in the rapidly growing robotic surgery market. 
